Current Trends in Targeted Therapies for Glioblastoma Multiforme
Figure 1
RTOG 0525/EORTC 26052-22053 (dose-dense) study. The study aimed to determine if intensified TMZ (75–100 mg/m2 × 21 days, q4weeks) improves overall survival or progression-free survival compared to the standard arm (150–200 mg/m2 × 5 days, q4weeks).
